A Phase 2 interventional study of Dupilumab and Timothy Grass SCIT in Allergic Rhinitis, sponsored by Regeneron Pharmaceuticals. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-05-28.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.
Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 45th largest by enrollment of the 119 interventional ones that give a count, is one of 4 that started in 2018, is one of 17 in phase 2, and was the 123rd registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–100
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18–60 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 4–100 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 23 · Phase 3 35 · Phase 4 25
First in 1996; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 54 across the 119 interventional studies, 60 across the 21 observational. Of the 122 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 141 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 3 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
3 of the studies in Rhinitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06623799QHSLab, Inc.Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study | 2027-01-25 |
| NCT05331170The University of Texas Medical Branch, GalvestonViral Mucosal Reprogramming | 2027-05-01 |
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 141 studies in Rhinitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic rhinitis symptoms, as measured by Total Nasal Symptom Score (TNSS) after nasal allergen challenge (NAC) with Timothy Grass extract at week 17.
The secondary objectives of the study are:
Key Inclusion Criteria:
Grass pollen allergy confirmed by both:
Key Exclusion Criteria:
Note: Other protocol defined inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
Drug: Placebo matching dupilumab · Drug: Placebo matching SCIT
Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
Drug: Dupilumab · Drug: Placebo matching SCIT
Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.
Drug: Timothy Grass SCIT · Drug: Placebo matching dupilumab
Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
Drug: Dupilumab · Drug: Timothy Grass SCIT
Dupilumab was administered SC in a single-use, pre-filled glass syringe
Also known as: DUPIXENT®, REGN668, SAR231893
Timothy grass extract was administered SC.
Placebo matching dupilumab was prepared in the same formulation without the addition of protein
Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing), each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.
Time frame: Baseline, Week 17
Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in SCIT vs. Dupilumab + SCIT
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.
Time frame: Baseline, Week 17
Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in Placebo vs. Dupilumab
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT group in this outcome measure.
Time frame: Baseline, Week 17
Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT.
Time frame: Baseline, Week 17
Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of responses for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.
Time frame: Baseline, Week 17
Percent Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.
Time frame: Baseline, Week 17
Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17
Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing values were imputed by Last Observation Carried Forward (LOCF) method for visits between post-baseline to Week 17.
Time frame: Baseline, Week 17
Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17
Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
Time frame: Baseline, Week 17
Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17
Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
Time frame: Baseline, Week 17
Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17
Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
Time frame: Baseline, Week 17
Change From Baseline in Log-Transformed Value of Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Serum Timothy Grass Specific Immunoglobulin E (sIgE) Ratio to Week 17
Biomarkers measured in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
Time frame: Baseline, Week 17
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 24\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
Time frame: Baseline through Week 24
A total of 214 participants were screened for study eligibility at 17 study sites in United States and Canada, of whom 103 were randomized to receive the study treatment. Screen failure was mostly due to inclusion criteria not met/exclusion criteria met.
| Milestone | Placebo | Dupilumab | SCIT | Dupilumab + SCIT |
|---|---|---|---|---|
| Started | 25 | 26 | 26 | 26 |
| Completed | 24 | 24 | 18 | 24 |
| Not completed | 1 | 2 | 8 | 2 |
| Withdrew: Adverse event | 0 | 2 | 5 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing), each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.
| Percent Change | SCIT | Dupilumab + SCIT |
|---|---|---|
| Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17 | -56.76 ± 9.687 | -52.03 ± 8.462 |
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.
| Score on a Scale*hour | SCIT | Dupilumab + SCIT |
|---|---|---|
| Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in SCIT vs. Dupilumab + SCIT | -3.07 ± 0.361 | -2.77 ± 0.321 |
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT group in this outcome measure.
| Score on a Scale*hour | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in Placebo vs. Dupilumab | -1.85 ± 0.323 | -1.83 ± 0.329 |
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT.
| Percent Change | Placebo | Dupilumab |
|---|---|---|
| Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 | -28.82 ± 8.427 | -21.57 ± 8.415 |
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of responses for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.
| Score on a Scale*hour | Dupilumab | Dupilumab + SCIT |
|---|---|---|
| Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 | -1.83 ± 0.329 | -2.77 ± 0.321 |
TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.
| Percent Change | Dupilumab | Dupilumab + SCIT |
|---|---|---|
| Percent Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 | -21.57 ± 8.415 | -52.03 ± 8.462 |
Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing values were imputed by Last Observation Carried Forward (LOCF) method for visits between post-baseline to Week 17.
| Milligram per Liter (mg/L) | SCIT | Dupilumab + SCIT |
|---|---|---|
| Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17 | 1.705 (0.520 to 6.090) | 3.550 (0.630 to 8.250) |
Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
| Percent Change | SCIT | Dupilumab + SCIT |
|---|---|---|
| Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17 | 1444.49 (650.00 to 2650.00) | 1896.25 (700.00 to 5050.00) |
Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
| Kilo Unit per Liter (kU/L) | SCIT | Dupilumab + SCIT |
|---|---|---|
| Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17 | 6.460 (2.750 to 15.900) | -2.990 (-10.890 to -0.940) |
Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
| Percent Change | SCIT | Dupilumab + SCIT |
|---|---|---|
| Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17 | 81.27 (21.27 to 179.41) | -56.44 (-68.00 to -37.20) |
Biomarkers measured in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.
| Ratio | SCIT | Dupilumab + SCIT |
|---|---|---|
| Change From Baseline in Log-Transformed Value of Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Serum Timothy Grass Specific Immunoglobulin E (sIgE) Ratio to Week 17 | 0.745 (0.210 to 1.400) | 1.720 (1.360 to 2.130) |
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 24\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
| Participants | Placebo | Dupilumab | SCIT | Dupilumab + SCIT |
|---|---|---|---|---|
| Participants with TEAEs | 21 | 18 | 24 | 22 |
| Participants with Serious TEAEs | 1 | 1 | 1 | 2 |
Collected over Adverse event information was collected from the time the informed consent was signed until the participant's last study visit, regardless of seriousness or relationship to investigational product.Treatment-emergent adverse events were reported for the 16-week treatment period and the 8-week follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/25 (0%) | 1/25 (4%) | 19/25 (76%) |
| Dupilumab | 0/26 (0%) | 1/26 (3.8%) | 16/26 (61.5%) |
| SCIT | 0/26 (0%) | 1/26 (3.8%) | 23/26 (88.5%) |
| Dupilumab + SCIT | 0/26 (0%) | 2/26 (7.7%) | 20/26 (76.9%) |
| Event | Placebo | Dupilumab | SCIT | Dupilumab + SCIT |
|---|---|---|---|---|
| Bipolar disorderPsychiatric disorders | 1/25 | 0/26 | 0/26 | 0/26 |
| HypersensitivityImmune system disorders | 0/25 | 0/26 | 1/26 | 0/26 |
| PyelonephritisInfections and infestations | 0/25 | 0/26 | 0/26 | 1/26 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 1/26 | 0/26 | 0/26 |
| AnxietyPsychiatric disorders | 0/25 | 0/26 | 0/26 | 1/26 |
| Event | Placebo | Dupilumab | SCIT | Dupilumab + SCIT |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 8/25 | 8/26 | 11/26 | 16/26 |
| NasopharyngitisInfections and infestations | 5/25 | 5/26 | 1/26 | 10/26 |
| HypersensitivityImmune system disorders | 0/25 | 0/26 | 4/26 | 8/26 |
| Upper respiratory tract infectionInfections and infestations | 5/25 | 4/26 | 1/26 | 0/26 |
| Injection site indurationGeneral disorders | 1/25 | 0/26 | 5/26 | 4/26 |
| Injection site erythemaGeneral disorders | 1/25 | 1/26 | 2/26 | 4/26 |
| Injection site pruritusGeneral disorders | 1/25 | 0/26 | 4/26 | 3/26 |
| NauseaGastrointestinal disorders | 3/25 | 0/26 | 2/26 | 2/26 |
| Viral upper respiratory tract infectionInfections and infestations | 3/25 | 0/26 | 0/26 | 1/26 |
| HeadacheNervous system disorders | 3/25 | 1/26 | 1/26 | 1/26 |
The full analysis set (FAS) included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Age, Continuous(Years) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| Mean | 34.6 ± 11.05 | 40.3 ± 11.19 | 37.8 ± 11.25 | 33.0 ± 10.58 | 36.5 ± 11.22 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| Female | 10 | 16 | 14 | 10 | 50 |
| Male | 15 | 10 | 12 | 16 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 | 1 | 11 |
| Not Hispanic or Latino | 21 | 24 | 21 | 25 | 91 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 3 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 4 | 2 | 12 |
| White | 20 | 18 | 17 | 21 | 76 |
| More than one race | 1 | 2 | 1 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| Total nasal symptom score (TNSS) Area under Curve (AUC) [0-1 hour (hr)] at Baseline(Score on a Scale*hour) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| Mean | 5.34 ± 2.175 | 5.03 ± 2.193 | 4.66 ± 1.987 | 4.69 ± 1.720 | 4.93 ± 2.015 |
| Timothy Grass Pollen IgG4(Miligram per Liter (mg/L)) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| Median | 0.080 (0.080 to 0.210) | 0.080 (0.080 to 0.170) | 0.080 (0.080 to 0.190) | 0.080 (0.080 to 0.210) | 0.080 (0.080 to 0.210) |
| Timothy Grass Specific Immunoglobulin E (sIgE)(Kilo Unit per Liter (kU/L)) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| Median | 9.640 (3.890 to 37.100) | 4.810 (1.800 to 17.600) | 10.300 (3.600 to 20.600) | 11.250 (3.010 to 17.700) | 9.180 (3.000 to 20.700) |
| Log Transformed Timothy Grass Pollen IgG4 vs sIgE ratio(Ratio) | Placebo | Dupilumab | SCIT | Dupilumab + SCIT | Total |
|---|---|---|---|---|---|
| Median | -1.970 (-2.390 to -1.460) | -1.515 (-2.150 to -1.220) | -1.860 (-2.110 to -1.650) | -1.975 (-2.340 to -1.170) | -1.840 (-2.300 to -1.350) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in May 2019, 11 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 31 phase 2 interventional studies under Rhinitis, Allergic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 11 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab